Biogen Inc (NASDAQ:BIIB)
| 230.88 Delayed Data As of 4:00pm ET |  -3.01 / -1.29%Today’s Change | 217.10 Today|||52-Week Range 468.55 | -3.77% Year-to-Date |
Latest BIIB News | Press Releases
| Ionis' (IONS) Partner to Begin New Huntington's Disease Study Jan 18 / Zacks.com - Paid Partner Content | 4 Biotech Acquisitions We'd Like to See in 2022 Jan 14 / MotleyFool.com - Paid Partner Content |
| Is Biogen a Buy After the Latest Aduhelm Disaster? Jan 17 / MotleyFool.com - Paid Partner Content | Longleaf Partners Comments on Biogen Jan 13 / GuruFocus News - Paid Partner Content |
| Where Will Biogen Be in 5 Years? Jan 15 / MotleyFool.com - Paid Partner Content | Longleaf Partners Fund's 4th-Quarter Commentary Jan 13 / GuruFocus News - Paid Partner Content |
| Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know Jan 14 / Zacks.com - Paid Partner Content | Why Biogen Stock Is Sinking Today Jan 12 / MotleyFool.com - Paid Partner Content |
| Biogen Is More Likely to Be a Buyer Than Seller Jan 14 / GuruFocus News - Paid Partner Content | Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs Jan 12 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 233.89 |
| Today’s open | 234.35 |
| Day’s range | 230.70 - 234.95 |
| Volume | 66,334 |
| Average volume (3 months) | 1,384,700 |
| Market cap | $35.2B |
Data as of 4:00pm ET, 01/19/2022
Growth & Valuation
| Earnings growth (last year) | -21.00% |
| Earnings growth (this year) | -42.95% |
| Earnings growth (next 5 years) | -4.00% |
| Revenue growth (last year) | -2.82% |
| P/E ratio | 22.1 |
| Price/Sales | 3.20 |
| Price/Book | 3.41 |
Competitors
| ---- | ||
| BMRNBiomarin Pharmaceuti... | -0.67 | -0.77% |
| TECHBio-Techne Corp | +0.30 | +0.08% |
| EXASExact Sciences Corp | -1.35 | -1.74% |
Data as of 4:00pm ET, 01/19/2022
Financials
| Next reporting date | January 27, 2022 |
| EPS forecast (this quarter) | $3.34 |
| Annual revenue (last year) | $12.4B |
| Annual profit (last year) | $4.0B |
| Net profit margin | 32.38% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
